HK1212207A1 - 經取代吡咯並嘧啶化合物、其組合物及其治療方法 - Google Patents

經取代吡咯並嘧啶化合物、其組合物及其治療方法

Info

Publication number
HK1212207A1
HK1212207A1 HK16100005.5A HK16100005A HK1212207A1 HK 1212207 A1 HK1212207 A1 HK 1212207A1 HK 16100005 A HK16100005 A HK 16100005A HK 1212207 A1 HK1212207 A1 HK 1212207A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treatment therewith
pyrrolopyrimidine compounds
substituted pyrrolopyrimidine
Prior art date
Application number
HK16100005.5A
Other languages
English (en)
Inventor
Andrew Antony Calabrese
Brandon David Jeffy
Dale Robinson
Dan Zhu
Dehua Huang
Jan Elsner
John Frederick Boylan
Lida Tehrani
Mark A Nagy
Raj Kumar Raheja
Paul Erdman
Rama K Narla
Roy L Harris
Tam Minh Tran
Jennifer R Riggs
Yuhong Ning
Shuichan Xu
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50031611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1212207(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of HK1212207A1 publication Critical patent/HK1212207A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK16100005.5A 2013-01-16 2016-01-04 經取代吡咯並嘧啶化合物、其組合物及其治療方法 HK1212207A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361753259P 2013-01-16 2013-01-16
PCT/US2014/011612 WO2014113429A2 (en) 2013-01-16 2014-01-15 Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
HK1212207A1 true HK1212207A1 (zh) 2016-06-10

Family

ID=50031611

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100005.5A HK1212207A1 (zh) 2013-01-16 2016-01-04 經取代吡咯並嘧啶化合物、其組合物及其治療方法

Country Status (24)

Country Link
US (3) US9428509B2 (zh)
EP (2) EP3202403A1 (zh)
JP (1) JP2016505041A (zh)
KR (1) KR20150108389A (zh)
CN (1) CN105188704B (zh)
AR (1) AR094494A1 (zh)
AU (1) AU2014207641A1 (zh)
BR (1) BR112015016997A2 (zh)
CA (1) CA2897985A1 (zh)
CL (1) CL2015001990A1 (zh)
EA (1) EA201591327A1 (zh)
EC (1) ECSP15030799A (zh)
ES (1) ES2638179T3 (zh)
HK (1) HK1212207A1 (zh)
IL (1) IL239901A0 (zh)
MX (1) MX2015009209A (zh)
NI (1) NI201500094A (zh)
NZ (1) NZ630467A (zh)
PE (1) PE20151995A1 (zh)
PH (1) PH12015501576A1 (zh)
SG (1) SG11201505446WA (zh)
TW (1) TW201441227A (zh)
WO (1) WO2014113429A2 (zh)
ZA (1) ZA201505011B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CA2897985A1 (en) 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP3169686A4 (en) * 2014-07-14 2018-01-24 Signal Pharmaceuticals, LLC Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016073771A2 (en) * 2014-11-06 2016-05-12 Ohio State Innovation Foundation Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
EP3778605A3 (en) 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
CN105906630B (zh) * 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
CN107709327A (zh) 2015-06-22 2018-02-16 小野药品工业株式会社 Brk抑制性化合物
WO2017011720A1 (en) * 2015-07-16 2017-01-19 Signal Pharmaceuticals, Llc Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN107531710B (zh) 2015-08-13 2020-02-14 北京韩美药品有限公司 Irak4抑制剂及其应用
JP2018538241A (ja) * 2015-10-13 2018-12-27 ザ スクリプス リサーチ インスティテュート 乳癌におけるカゼインキナーゼ１δの治療標的化
MX2018005696A (es) 2015-11-06 2018-11-09 Samumed Llc Tratamiento de la osteoartritis.
CN105646496B (zh) * 2016-01-20 2018-07-20 华侨大学 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用
CN108727400B (zh) * 2017-05-24 2021-07-09 四川晶华生物科技有限公司 一种治疗肿瘤的化合物
CU20200038A7 (es) * 2017-10-27 2021-03-11 Bayer Ag Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
CA3084962C (en) 2017-12-28 2022-08-09 Daewoong Pharmaceutical Co., Ltd. Oxy-fluoropiperidine derivatives as kinase inhibitor
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
EP3731845A4 (en) * 2017-12-28 2021-10-06 Development Center for Biotechnology HETEROCYCLIC COMPOUNDS AS TYRO3, AXL AND MERTK (TAM) FAMILY OF RECEPTOR TYROSINKINASE INHIBITORS
CN112512522A (zh) * 2018-05-15 2021-03-16 田纳西大学研究基金会 用于三阴性乳腺癌和卵巢癌的治疗的化合物
WO2020150552A2 (en) 2019-01-17 2020-07-23 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
CA3214894A1 (en) * 2021-04-30 2022-11-03 Yuli Xie Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
KR102582916B1 (ko) * 2021-05-03 2023-09-26 주식회사 제이비케이랩 2,6-디클로로-4-(4-(4-하이드록시사이클로헥실아미노)-7H-피롤로[2,3-d]피리미딘-5-일)페놀을 유효성분으로 포함하는 암의 예방, 개선 또는 치료용 약학적 조성물

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3567725A (en) 1968-11-20 1971-03-02 Merck & Co Inc Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4294836A (en) 1980-03-24 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
US4294837A (en) 1980-03-28 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
US4317909A (en) 1980-03-24 1982-03-02 Sterling Drug Inc. Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
US4309537A (en) 1980-03-28 1982-01-05 Sterling Drug Inc. Production of imidazo[4,5-b]pyridin-2-ones or thiones
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
JPS63275582A (ja) 1987-05-02 1988-11-14 Naade Kenkyusho:Kk ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
DD262026A1 (de) 1987-07-10 1988-11-16 Akad Wissenschaften Ddr Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
TW274550B (zh) 1992-09-26 1996-04-21 Hoechst Ag
DE19601627A1 (de) 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
US6031105A (en) 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
EP1017384B1 (en) 1997-09-26 2004-11-10 Zentaris GmbH Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP2003146987A (ja) 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
JP3814125B2 (ja) 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
JP2002100363A (ja) 2000-09-25 2002-04-05 Mitsubishi Chemicals Corp リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
JP2002167387A (ja) 2000-11-29 2002-06-11 Dainippon Pharmaceut Co Ltd ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
JP2004520299A (ja) 2000-12-12 2004-07-08 ニューロジェン・コーポレーション スピロ［イソベンゾフラン−１，４’−ピペリジン］−３−オン類及び３ｈ−スピロイソベンゾフラン−１，４’−ピペリジン類
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
CA2458699C (en) 2001-09-04 2010-10-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
NZ536123A (en) 2002-05-06 2006-09-29 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
US20040204420A1 (en) 2002-08-05 2004-10-14 Rana Tariq M. Compounds for modulating RNA interference
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
CA2512646A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
SI1599478T1 (sl) 2003-02-26 2007-10-31 Boehringer Ingelheim Pharma Dihidropteridinoni, postopek za njihovo pripravo in njihova uporaba kot zdravila
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JP2006524289A (ja) 2003-04-23 2006-10-26 ワイス・ホールディングズ・コーポレイション Ｐｅｇ−ワートマニンコンジュゲート
SI1633766T1 (sl) 2003-05-30 2019-06-28 Gilead Pharmasset Llc Modificirani analogi fluoriranih nukleozidov
WO2005013894A2 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
CA2569406A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006001266A1 (ja) 2004-06-23 2006-01-05 Banyu Pharmaceutical Co., Ltd. ２－アリールプリン誘導体の製造方法
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006036883A2 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
CA2577588C (en) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
MX2007012393A (es) 2005-04-05 2008-02-22 Pharmacopeia Inc Derivados de purina e imidazopiridina para la inmunosupresion.
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
AU2007281468B2 (en) 2006-08-02 2012-12-06 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
EP2364702A3 (en) 2006-09-05 2012-01-25 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
US20100144738A1 (en) 2006-09-05 2010-06-10 William Bornmann Inhibitors of c-met and uses thereof
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
KR101504669B1 (ko) 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
CN101679432B (zh) 2006-10-19 2015-04-22 西格诺药品有限公司 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2011516580A (ja) 2008-04-11 2011-05-26 バイオノボ・インコーポレーテッド トウサイカチｇｌｅｄｉｔｓｉａｓｉｎｅｎｓｉｓｌａｍの抽出物を用いる抗癌方法
WO2009131687A2 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
EP3091021B1 (en) 2009-10-26 2019-08-28 Signal Pharmaceuticals, LLC Methods of synthesis and purification of heteroaryl compounds
EP2531194B1 (en) 2010-02-03 2018-04-18 Signal Pharmaceuticals, LLC Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
US20120028972A1 (en) 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
CN105039520A (zh) 2011-08-03 2015-11-11 西格诺药品有限公司 作为lkb1状态的预测性生物标志物的基因表达谱的鉴定
UA110259C2 (uk) * 2011-09-22 2015-12-10 Пфайзер Інк. Похідні піролопіримідину і пурину
TWI708605B (zh) 2011-10-19 2020-11-01 標誌製藥公司 以ｔｏｒ激酶抑制劑治療癌症
IN2014CN04037A (zh) 2011-12-02 2015-10-23 Signal Pharm Llc
ES2742398T3 (es) 2012-02-24 2020-02-14 Signal Pharm Llc Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa
EP2825170B1 (en) 2012-03-15 2018-05-09 Signal Pharmaceuticals, LLC Treatment of cancer with tor kinase inhibitors
WO2013138560A1 (en) 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
MY182650A (en) 2012-03-15 2021-01-27 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
KR102181365B1 (ko) * 2012-08-06 2020-11-23 에이시아 바이오사이언시스 인코포레이티드. 단백질 키나아제 억제제로서 새로운 피롤로피리미딘 화합물
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2013202768B2 (en) 2012-10-18 2015-11-05 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
CA2897985A1 (en) 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
TW201441227A (zh) 2014-11-01
KR20150108389A (ko) 2015-09-25
US9795607B2 (en) 2017-10-24
EP2945636A2 (en) 2015-11-25
PH12015501576A1 (en) 2016-02-01
WO2014113429A2 (en) 2014-07-24
NI201500094A (es) 2015-09-21
PE20151995A1 (es) 2016-01-13
BR112015016997A2 (pt) 2017-07-11
EA201591327A1 (ru) 2015-12-30
MX2015009209A (es) 2016-03-17
CN105188704B (zh) 2017-09-19
EP2945636B1 (en) 2017-06-28
US20160324861A1 (en) 2016-11-10
CA2897985A1 (en) 2014-07-24
JP2016505041A (ja) 2016-02-18
NZ630467A (en) 2017-02-24
ECSP15030799A (es) 2015-11-30
CN105188704A (zh) 2015-12-23
EP3202403A1 (en) 2017-08-09
IL239901A0 (en) 2015-08-31
WO2014113429A3 (en) 2014-10-09
US20140200206A1 (en) 2014-07-17
SG11201505446WA (en) 2015-08-28
AR094494A1 (es) 2015-08-05
US20140200207A1 (en) 2014-07-17
US9346812B2 (en) 2016-05-24
AU2014207641A1 (en) 2015-08-06
ES2638179T3 (es) 2017-10-19
CL2015001990A1 (es) 2016-01-22
ZA201505011B (en) 2016-11-30
US9428509B2 (en) 2016-08-30

Similar Documents

Publication Publication Date Title
HK1212207A1 (zh) 經取代吡咯並嘧啶化合物、其組合物及其治療方法
IL246252A0 (en) Diaminopyrimidyl derivative compounds, their compositions and methods of treatment
IL277069B (en) Modified aminopurine compounds, their compositions and methods of treatment with them
IL245184A0 (en) Prostacyclin compounds, preparations and methods of using them
IL273090B (en) Methods and preparations for the treatment of cancer
EP2986140A4 (en) COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
GB201320723D0 (en) Composition and methods of treatment
IL244066A0 (en) Triazolopyridine compounds, preparations and methods for their use
SG11201510594YA (en) Mixtures of compounds, their preparation, and uses
SG11201505220VA (en) Prevention & treatment of neuropathy
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
EP2967055A4 (en) BIOCIDAL COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
EP2800568A4 (en) COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
HK1217715A1 (zh) 治療中風的組合物及方法
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity